Table 5.
Association between log adiponectin and 1-year composite outcomes of all-cause mortality or hospitalization for heart failure (N = 120).a
| All-cause mortality (no. of outcomes = 10) | Hospitalization for heart failure (no. of outcomes = 9) | Composite of all-cause hospitalization mortality and for heart failure (no. of outcomes = 14) | ||||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| Unadjusted models | HR | p | HR | p | HR | p |
| Age | 1.11 | <0.001 | 1.08 | 0.011 | 1.09 | <0.001 |
| Sex, men | 0.28 | 0.046 | 0.19 | 0.021 | 0.30 | 0.025 |
| BMI | 0.81 | 0.043 | 0.76 | 0.016 | 0.82 | 0.021 |
| DM | 1.44 | 0.60 | 1.64 | 0.48 | 1.32 | 0.64 |
| History of MI | 5.68 | 0.012 | 2.94 | 0.10 | 3.12 | 0.035 |
| History of HF | 9.74 | <0.001 | 18.0 | <0.001 | 10.3 | <0.001 |
| Log hs-CRP (mg/L) | 3.25 | 0.024 | 3.91 | 0.034 | 3.20 | 0.014 |
| BNP (pg/mL) | 1.00 | 0.16 | 1.00 | 0.29 | 1.00 | 0.13 |
| GIK treatment | 0.29 | 0.12 | 0.14 | 0.07 | 0.31 | 0.07 |
| Log adiponectin, per 1 μg/mL | 0.54 | 0.20 | 0.43 | 0.10 | 0.51 | 0.09 |
| Adiponectin quartiles | ||||||
| Quartile 1 | Ref | Ref | Ref | Ref | Ref | Ref |
| Quartile 2 | 0.20 | 0.14 | 0.50 | 0.42 | 0.50 | 0.33 |
| Quartile 3 | 0.69 | 0.61 | 0.58 | 0.50 | 0.74 | 0.64 |
| Quartile 4 | 0.20 | 0.15 | 0.25 | 0.21 | 0.17 | 0.10 |
BMI: body mass index; BNP: brain-type natriuretic peptide; GIK: glucose–insulin–potassium; Hgb A1C: glycosylated haemoglobin; HF: heart failure; HR: hazard ratio; hs-CRP: high-sensitivity C-reactive protein; MI: myocardial infarction.
a
First available adiponectin measurement for each participant was used in this analysis.